GLP-1 Drugs Overtake other Weight Loss Medications
Self-Administered Retatrutide Emerges as Best-in-Class
By Peter A. McCullough, MD, MPH
It is remarkable to see large amounts of weight loss in substantial numbers of people. No doubt GLP-1 receptor agonists are being used. The GLP-1 medications approved for weight loss by the FDA include Saxenda (liraglutide) and Wegovy (semaglutide), as well as Zepbound (tirzepatide). These are all glucagon-like peptide-1 receptor agonists that help reduce appetite and food intake, leading to reductions in adipose and skeletal muscle tissue. A recent update in JAMA indicated that Ozempic-like drugs have overtaken less expensive stimulants just as phentermine which is marketed under many brand names and formulations worldwide, including Acxion, Adipex, Adipex-P, Duromine, Elvenir, Fastin, Ionamin, Lomaira (phentermine hydrochloride), Panbesy, Qsymia (phentermine and topiramate), Razin, Redusa, Sentis, Suprenza, and Terfamex. .
However, most want to be free of clinic visits and needles and control their own weight journey with self-administration. Retatrutide is a groundbreaking triple agonist targeting glucagon receptors, gastric inhibitory polypeptide, and glucagon-like peptide-1, synergistically enhancing insulin secretion, improving glucose homeostasis, and refining appetite modulation. It is widely expected to be markedly by Eli Lilly after FDA approval in 2026.
Please subscribe to FOCAL POINTS as a paying ($5 monthly) or founder member so we can continue to bring you the truth.
Peter A. McCullough, MD, MPH
Chief Scientific Officer, The Wellness Company
While many people have had success losing weight with these drugs, a lot of doctors don’t seem to be aware or care that others have suffered very serious and long-lasting side effects.
I am in the latter class and went through “My year of living painfully,” as documented in my Substack article of that name. Thankfully, my symptoms finally did subside after almost a year, although many others have not been so fortunate.
I don’t know anything about the so-called best in class drug that the Good Doctor is touting here, however, I would urge great caution for anybody considering the use of any of this class of drugs!
Remember, there is no such thing as a free lunch!
Dr. McCullough don’t be a shill. The ethical error you made in this article shows a blind spot a mile wide. Seems like you attack the jab when you don’t have a financial interest but conveniently look the other way when you do. No mention of side effects, which are subatantial and significant.
This is more evidence that financial interest determines ’medical ethics’. I expected better from you but it looks like putting patient well being above your getting paid is too big an ask. Please address this issue.